IGHE and asthma: The introduction of biologics (Omalizumab, Mepolizumab, Benralizumab, Dupilumab and Tezepelumab) has decisively changed the management of patients with severe asthma, significantly reducing exacerbations and the use of OCS, and improving respiratory function and quality of life, allowing for a personalized approach based on biomarkers (FeNO, eosinophil count, IgE).